Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Less Frequent Dosing of Daratumumab in Newly Diagnosed Multiple Myeloma
NCT07891923Phase 2Recruiting
- Sponsor
- Tata Memorial Centre
- Start
- Oct 2025
- Primary completion
- May 2029
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), sponsored by Tata Memorial Centre. Started Oct 2025; status: recruiting.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07891923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07891923.